<p>NEW YORK (Reuters) Amylin Pharmaceuticals Inc , that spurned a $3.5 billion takeover bid from Bristol-Myers Squibb Co and is fending off a lawsuit from romantic financier Carl Icahn, started reaching out to intensity buyers final week, sources informed with a conditions pronounced on Sunday.
Amylin, builder of diabetes drugs Byetta and Bydureon, has hired Credit Suisse and Goldman Sachs as a financial advisers and Skadden Arps as a authorised adviser, a sources said.
Amylin and a advisers declined to comment.
Analysts have pronounced several drug companies could be intensity buyers for Amylin, including AstraZeneca Plc , Merck Co and Takeda Pharmaceutical Co Ltd .
The pierce comes amid broader converging in a medical sector. Big curative companies have been creation assertive bids for earnest biotech firms and other targets as they demeanour to find new products and feed their pipelines. These large firms are also f...
Monday, 23 April 2012
0 comments
Post a Comment